In Process Citation
There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib. Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Nuklearmedizin |
| Sprache: |
Deutsch |
|---|
| Beteiligte Personen: |
Lindner, Christina [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC196411411X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC196411411X | ||
| 003 | DE-627 | ||
| 005 | 20230518132629.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||ger c | ||
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC196411411X | ||
| 035 | |a (DE-599)GBVOLC196411411X | ||
| 035 | |a (PRQ)pubmed_primary_254211380 | ||
| 035 | |a (KEY)0026443120150000054000300125inprocesscitation | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a 44.64 |2 bkl | ||
| 100 | 1 | |a Lindner, Christina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Process Citation |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib. Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists. | ||
| 700 | 1 | |a Dierneder, J |4 oth | |
| 700 | 1 | |a Pall, G |4 oth | |
| 700 | 1 | |a Pirich, C |4 oth | |
| 700 | 1 | |a Hoffmann, M |4 oth | |
| 700 | 1 | |a Raderer, M |4 oth | |
| 700 | 1 | |a Becherer, A |4 oth | |
| 700 | 1 | |a Niederle, B |4 oth | |
| 700 | 1 | |a Lipp, R |4 oth | |
| 700 | 1 | |a Lind, P |4 oth | |
| 700 | 1 | |a Gallowitsch, H |4 oth | |
| 700 | 1 | |a Romeder, F |4 oth | |
| 700 | 1 | |a Virgolini, I |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nuklearmedizin <Stuttgart, 1959/61 - 1983; 1988 -> |d Stuttgart : Thieme, 1959 |g 54(2015), 3, Seite 125 |w (DE-627)12930333X |w (DE-600)123578-3 |w (DE-576)014497298 |x 0029-5566 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2015 |g number:3 |g pages:125 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25421138 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4027 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 936 | b | k | |a 44.64 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 54 |j 2015 |e 3 |h 125 | ||